PDF下载 ( 221 KB)
Endocannabinoid receptors and nonalcoholic steatohepatitis
-
-
[1]Charlton M.Cirrhosis and live failure in nonalcoholic fatty liver dis-ease:Malehill or mountain-[J].Hepatology, 2008, 47 (5) :1431-1433. [2]Wiedkowska A, McCulloug AJ, Feldstein AE.Noninvasive diagno-sis and montoring of nonalcoholic steatohepatitis:Present and future[J].Hepatology, 2007, 46 (2) :582-589. [3]Fan JG, Zhu J, Li XJ, et al.Prevalence and risk factors for fatty liv-er in a general population of shanghai, China[J].J Hepatology, 2005, 43 (3) :505-514. [4]万燕萍, 徐仁应, 方华, 等.上海地区1180名在校儿童非酒精性脂肪性肝病检出率及危险因素分析[J].中华肝脏病杂志, 2007, 15 (9) :644-653. [5]Ekstedt M, Franzen LE, Mathiesen UL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatolo-gy, 2006, 44 (4) :865-873. [6]Yamazaki Y, Kakizaki S, Horiguchi N, et al.The role of the nucle-ar receptor constitutive androstane receptor in the pathogenesis of non-alocholic steatohepatitis[J].Gut, 2007, 56 (4) :565-574. [7]Li ZZ, Berk M, Mclntyre TM, et al.The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity[J].Hepatology, 2008, 47 (5) :1495-1503. [8]Devan WA, Hanus L, Breuer A, et al.Isolation and structure of a brain constituent that bind to the cannabinoid receptor[J].Science, 1992, 258 (5090) :1946-1949. [9]Siegmund SV.Uchinami H, Osawa Y, et al.Anandamide indues nerosis in primary hepatic stellate cell[J].Hepology, 2005, 41 (4) :1085-1095. [10]Kunos G, Gao B.Endocannabinoids, CB1receptors, and liver disease:Hitting more than one bird with the same stone[J].Gastro-enterology, 2008, 134 (2) :622-625. [11]Osei-Hyiaman D, Depetrillo M, Pacher P, et al.Endocannabi-noid activation at hepatic CB1receptors stimulates fatty acid synthesis and contributes to diet-induced obesity[J].J Clin Invest, 2005, 115 (5) :1298-1305. [12]Teixeira-Clerc F, Julien B, Grenard P, et al.CB1cannabinoid receptor antagonism:a new strategy for the treatment of liver fibrosis[J].Nat Med, 2006, 12 (6) :671-676. [13]Batkai S, Osei-Hyiaman D, Pan H, et al.Cannabind-2receptor nudiates protection against hepatic ischemia/reperfusion injury[J].Faseb J, 2007, 21 (8) :1788-1800. [14]Julien B, Grenard P, Teixeira-Clerc F, et al.Antifibrogenic role of the cannabinoid receptor CB2in the liver[J].Gastroenterology, 2005, 128 (3) :742-755. [15]Osei-Hyiaman D, Liu J, Zhou L, et al.Hepatic CB1receptor is required for development of diet-induced ssteatosis, dyslipimia, and insulin and leptin resistanance in mice[J].J Clin Inevest, 2008, 118 (9) :3160-3169. [16]Wasmuth HE, Trautwein C.Hepatic steatosis and endocannabi-noids-Does it all happen within the liver-[J].Hepatology, 2008, 48 (6) :2080-2082. [17]Izzo AA, Camilleri M.Emerging role of Cannabinoids in gastroin-testinal and liver diseases:basic and clinical aspects[J].Gut, 2008, 57 (8) :1140-1155. [18]Jeong WI, Osei-Hyiaman D, Park O, et al.Paracrine activation of hepatic CB1receptors by stellate cell-derived endocannabinoids me-diates alcoholic fatty liver[J].Cell Metab, 2008, 7 (3) :227-235. [19]Deleve LD, Wang X, Kanel DC, et al.Prevention of hepatic fibro-sis in a murine model of metabolic syndrome with nonalcoholic steato-hepatitis[J].Am J Pathol, 2008, 173 (4) :993-1001. [20]Hezode C, Zafrani ES, Roudot-Thoraval F, et al.Daily cannabis use:a novel risk factor of steatosis severity in patients with chronic hepatitis C[J].Gastroenterology, 2008, 134 (2) :432-439. [21]Despres JP, Golay A, sjostrom L, et al.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia[J].N Engl J Med, 2005, 353 (20) :2121-2134. [22]Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.Effect of rimonabant, acannabinoid-1receptor blocker, on weight and cardi-ometabolic risk factors in overweight or obese patients:RIO-North Aerica:arandomized controlled trial[J].JAMA, 2006, 295 (7) :761-775. [23]Van Gaal LF, Rissanen AM, Scheen AJ, et al;Effects of the can-nabinoid-1receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study[J].Lancet, 2005, 365 (9468) :1389-1397. [24]Scheen AJ, Finer N, Hollander P, et al.Efficacy and tolerability of rimonabant in overweight or obese patients with type2diabetes:a randomised controlled study[J].Lancet, 2006, 368 (9548) :1660-1672. [25]Wasmuth HE, Trartwein C.CB1cannabinoid receptor antagonism:A new strategy for the treatment of liver fibrosis[J].Hepatology, 2007, 45 (2) :543-545. [26]Siegmund SV, Qian T, de Minicis S, et al.The endocannabinoid2-arachidonoyl glycerol induces death of hepatic stellate cells via mi-tochondrial reactive oxygen species[J].Faseb J, 2007, 21 (11) :2798-2806. [27]Baranova A, Liotta, Petricoin E, et al.The role of genomics and proteomics.Technologies in studying non-alcoholic fatty liver dis-ease[J].Clin Liv Dis, 2007, 11 (1) :207-220. [28]Huang H, Shiffman ML, Cheung RC, et al.Identification of two gene variant associated with risk of advanced fibrosis in patiens with chronic hepatitis C[J].Gastroenterology, 2006, 130 (6) :1679-1687. [29]Huang H, Shiffman ML, friedmen S, et al.A7gene Signateere i-dentifies the risk of developing cirrhosis in patients with chronic hep-atitis C[J].Hepatology, 2007, 46 (2) :297-306. [30]Gatti D, Maki A, Chesler EJ, et al.Genome-level analysis of ge-netic regulation of liver gene expression networks[J].Hepatology, 2007, 46 (2) :548-557. [31]Lai KKY, Klippakkam D, Beretta L.Comprehensive and quantita-tive proteome profiling of mouse liver and plasma[J].Hepatology, 2008, 47 (3) :1043-1051. [32]Tomes DM, Harrison SA.Diagnosis and therapy of nonalcoholic steatohepatitis[J].Gastroenterology, 2008, 134 (6) :1682-1698. [33]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenter-ology, 2008, 134 (6) :1655-1669. -
本文二维码
计量
- 文章访问数: 3052
- HTML全文浏览量: 3
- PDF下载量: 1147
- 被引次数: 0
下载:
